Next generation approaches for tumor vaccination.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Chinese Clinical Oncology

• Publication date

  2017-05-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.21037/cco.2017.02.04PMID 28482672
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy.

  2016cited by this paper
• CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.

  2015influential reference
• Oncolytic viruses: a new class of immunotherapy drugs

  2015cited by this paper
• The future of immune checkpoint therapy

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer.

  2015cited by this paper
• T cell exclusion, immune privilege, and the tumor microenvironment

  2015cited by this paper
• Final data from CALM: A phase II study of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma.

  2015cited by this paper
• Immunotherapy Converts Nonimmunogenic Pancreatic Tumors into Immunogenic Foci of Immune Regulation

  2014cited by this paper
• Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma

  2014cited by this paper
• Chimeric antigen receptor T-cell therapy for ALL.

  2014cited by this paper
• Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.

  2014cited by this paper
• Genetic basis for clinical response to CTLA-4 blockade in melanoma.

  2014cited by this paper
• Oncology meets immunology: the cancer-immunity cycle.

  2013cited by this paper
• Genetically engineered mouse models of cancer reveal new insights about the antitumor immune response.

  2013cited by this paper
• Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas.

  2013cited by this paper
• Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.

  2013cited by this paper
• Immune Modulation and Stereotactic Radiation: Improving Local and Abscopal Responses

  2013cited by this paper
• Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective.

  2012cited by this paper
• MUC1 Vaccine for Individuals with Advanced Adenoma of the Colon: A Cancer Immunoprevention Feasibility Study

  2012cited by this paper
• Radiation therapy to convert the tumor into an in situ vaccine.

  2012cited by this paper
• Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

  2011cited by this paper
• gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

  2011cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma.

  2010cited by this paper
• Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

  2010cited by this paper
• Live, attenuated strains of Listeria and Salmonella as vaccine vectors in cancer treatment

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Global implementation of human papillomavirus (HPV) vaccine: lessons from hepatitis B vaccine.

  2010cited by this paper
• The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix.

  2009cited by this paper
• Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation.

  2009cited by this paper
• Fractionated but Not Single-Dose Radiotherapy Induces an Immune-Mediated Abscopal Effect when Combined with Anti–CTLA-4 Antibody

  2009cited by this paper
• Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

  2007cited by this paper
• Sensors of ionizing radiation effects on the immunological microenvironment of cancer

  2007cited by this paper
• Inflammation and cancer: a double-edged sword.

  2007cited by this paper
• Adaptive immunity maintains occult cancer in an equilibrium state

  2007cited by this paper
• Prophylactic human papillomavirus vaccines.

  2006cited by this paper
• Combining a Recombinant Cancer Vaccine with Standard Definitive Radiotherapy in Patients with Localized Prostate Cancer

  2005cited by this paper
• Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide.

  2005cited by this paper
• Combination of Conformal Radiotherapy and Intratumoral Injection of Adoptive Dendritic Cell Immunotherapy in Refractory Hepatoma

  2005cited by this paper
• Cancer immunotherapy: moving beyond current vaccines

  2004cited by this paper
• [Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus].

  2004cited by this paper
• Systemic Therapy of Malignant Human Melanoma Tumors by a Common Cold-Producing Enterovirus, Coxsackievirus A21

  2004cited by this paper
• Coxsackievirus A21 binds to decay-accelerating factor but requires intercellular adhesion molecule 1 for cell entry

  1997cited by this paper

• Immunotherapy in Triple-Negative Breast Cancer: From Molecular Mechanisms to Precision Medicine-Overcoming Resistance and Optimizing Clinical Outcomes.

  2026cites this paper
• Tumor microenvironment: recent advances in understanding and its role in modulating cancer therapies

  2025cites this paper
• Combination of racotumomab immunotherapy with programmed death-1 blockade in a preclinical model of non-small cell lung cancer

  2025cites this paper
• Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy

  2021cites this paper
• Self-assembled peptide and protein nanostructures for anti-cancer therapy: Targeted delivery, stimuli-responsive devices and immunotherapy.

  2021cites this paper
• Neoantigen‐based vaccines as a promising strategy in cancer immunotherapeutics

  2021cites this paper
• Magnetic Nanostructures as Emerging Therapeutic Tools to Boost Anti-Tumour Immunity

  2021cites this paper
• Clinical significance of novel identified high‐frequency tumor‐specific peptides associated signature in predicting disease status of gastric cancer patients

  2021cites this paper
• A splenic-targeted versatile antigen courier: iPSC wrapped in coalescent erythrocyte-liposome as tumor nanovaccine

  2021cites this paper
• Cancer immunotherapy: Classification, therapeutic mechanisms, and nanomaterial-based synergistic therapy

  2021cites this paper
• Principles in Immunology for the Design and Development of Vaccines.

  2021cites this paper
• A novel self-assembled epitope peptide nanoemulsion vaccine targeting nasal mucosal epithelial cell for reinvigorating CD8+ T cell immune activity and inhibiting tumor progression.

  2021cites this paper
• Immuntherapeutische Therapieansätze – ein Überblick

  2020cites this paper
• TNFSF14: LIGHTing the Way for Effective Cancer Immunotherapy

  2020cites this paper
• Stimuli-responsive and cellular targeted nanoplatforms for multimodal therapy of skin cancer.

  2020cites this paper
• Immune Modulation in Lung Cancer: Current Concepts and Future Strategies

  2020cites this paper
• Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

  2019cites this paper
• Reproductive toxicity of perchlorate in rats.

  2019cites this paper
• Grundlagen der Krebsimmuntherapie

  2018cites this paper
• Immunoregulatory antigens-novel targets for cancer immunotherapy.

  2018cites this paper
• MHC class II restricted neoepitope vaccine: Promising strategy for immunotherapy.

  2018cites this paper
• The Prediction and Function of Neoantigen in Oncobiology

  2017cites this paper
• Grundlagen der Krebsimmuntherapie

  2017cites this paper